Formosa Laboratories Inc - Asset Resilience Ratio
Formosa Laboratories Inc (4746) has an Asset Resilience Ratio of 8.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Formosa Laboratories Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Formosa Laboratories Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 4746 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Formosa Laboratories Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Formosa Laboratories Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.22 Billion | 8.94% |
| Total Liquid Assets | NT$1.22 Billion | 8.94% |
Asset Resilience Insights
- Limited Liquidity: Formosa Laboratories Inc maintains only 8.94% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Formosa Laboratories Inc Industry Peers by Asset Resilience Ratio
Compare Formosa Laboratories Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.48% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
Annual Asset Resilience Ratio for Formosa Laboratories Inc (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Formosa Laboratories Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.78% | NT$1.35 Billion ≈ $42.64 Million |
NT$13.83 Billion ≈ $435.83 Million |
+0.15pp |
| 2024-12-31 | 9.64% | NT$1.34 Billion ≈ $42.18 Million |
NT$13.90 Billion ≈ $437.78 Million |
+2.42pp |
| 2023-12-31 | 7.22% | NT$984.48 Million ≈ $31.02 Million |
NT$13.64 Billion ≈ $429.61 Million |
+4.47pp |
| 2022-12-31 | 2.75% | NT$351.07 Million ≈ $11.06 Million |
NT$12.75 Billion ≈ $401.72 Million |
-0.28pp |
| 2021-12-31 | 3.03% | NT$363.95 Million ≈ $11.47 Million |
NT$12.02 Billion ≈ $378.60 Million |
+0.78pp |
| 2020-12-31 | 2.25% | NT$231.22 Million ≈ $7.28 Million |
NT$10.29 Billion ≈ $324.06 Million |
+1.98pp |
| 2019-12-31 | 0.27% | NT$26.09 Million ≈ $821.88K |
NT$9.61 Billion ≈ $302.72 Million |
+0.20pp |
| 2018-12-31 | 0.07% | NT$6.09 Million ≈ $191.77K |
NT$8.73 Billion ≈ $274.89 Million |
+0.07pp |
| 2012-12-31 | 0.00% | NT$177.00K ≈ $5.58K |
NT$4.04 Billion ≈ $127.14 Million |
+0.00pp |
| 2011-12-31 | 0.00% | NT$67.00K ≈ $2.11K |
NT$3.11 Billion ≈ $98.09 Million |
-0.02pp |
| 2010-12-31 | 0.02% | NT$438.00K ≈ $13.80K |
NT$2.38 Billion ≈ $74.83 Million |
-- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more